The reaffirmation of the Outperform rating and the maintenance of a $12 price target by a reputable analyst like Brian Abrahams from RBC Capital could instill confidence among investors and potentially lead to a positive short-term impact on Applied Therapeutics' stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor perception and stock performance in the short term.